SC slams Patanjali for prima facie violation of undertaking on claims of medicinal efficacy

New Delhi: The Supreme Court on Tuesday came down heavily on yoga guru Ramdev's Patanjali Ayurved for prima facie violation of the undertaking it gave in the court about its products and statements claiming their medicinal efficacy.

A bench of Justices Hima Kohli and A Amanullah issued a notice to Patanjali Ayurved and its managing director asking why contempt proceedings should not be initiated against them.

The bench also cautioned Patanjali Ayurved and its officers from making any statements adverse to any system of medicine in the media, both print and electronic, in any form as they said in their undertaking before the court earlier.

On November 21, 2023, the counsel representing the company assured the apex court that henceforth there shall not be any violation of law, especially relating to advertising or branding of products, and no casual statements claiming medicinal efficacy of Patanjali products or against any system of medicine will be released to the media in any form.

The apex court had then cautioned the company, co-founded by Ramdev and dealing in herbal products, against making "false" and "misleading" claims in advertisements about its medicines as a cure for several diseases. The top court is hearing a plea of the Indian Medical Association (IMA) alleging a smear campaign by Ramdev against the vaccination drive and modern medicines.